The report titled “Global Refractory Status Epilepticus (RSE) - Patient & Segmentation, Historical and Forecast to 2029” offers strategic insights into the global RSE patient population along with the Patient Segmentation and estimates for the duration 2018 to 2029.
Refractory status epilepticus is defined as persistent seizures despite appropriate use of two intravenous medications, one of which is a benzodiazepine. It can be seen in up to 40% of cases of status epilepticus with an acute symptomatic etiology as the most likely cause. New-onset refractory status epilepticus (NORSE) is a recently coined term for refractory status epilepticus where no apparent cause is found after initial testing
The seven major incidence of Refractory Status Epilepticus (RSE) is expected to grow at a CAGR of around 0.55% during 2018-2029. It has been observed that approximately 30-40% of status epilepticus patient are refractory to first and second line treatment (known as refractory status epilepticus) throughout the seven major market. The United States have the majority of the patient population
Historical & Forecast Period
Report’s Scope
The purpose of this strategic research study titled “Global Refractory Status Epilepticus (RSE) - Patient & Segmentation, Historical and Forecast to 2029” is to offer industry investors, company executives, and industry participants with in-depth insights to enable them make informed strategic decisions related to the opportunities in the global refractory status epilepticus (RSE) market. The said research study covers in-depth analysis of affected patient population and its segmentation by geography. The report covers the patient population by gender as well as by age along with all the assumptions considered in different geographies.
Patient Segmentation
Regional Segmentation
Refractory status epilepticus is defined as persistent seizures despite appropriate use of two intravenous medications, one of which is a benzodiazepine. It can be seen in up to 40% of cases of status epilepticus with an acute symptomatic etiology as the most likely cause. New-onset refractory status epilepticus (NORSE) is a recently coined term for refractory status epilepticus where no apparent cause is found after initial testing
The seven major incidence of Refractory Status Epilepticus (RSE) is expected to grow at a CAGR of around 0.55% during 2018-2029. It has been observed that approximately 30-40% of status epilepticus patient are refractory to first and second line treatment (known as refractory status epilepticus) throughout the seven major market. The United States have the majority of the patient population
Historical & Forecast Period
- Base Year: 2018
- Historical Period: 2018-2019
- Forecast Period: 2020-2029
Report’s Scope
The purpose of this strategic research study titled “Global Refractory Status Epilepticus (RSE) - Patient & Segmentation, Historical and Forecast to 2029” is to offer industry investors, company executives, and industry participants with in-depth insights to enable them make informed strategic decisions related to the opportunities in the global refractory status epilepticus (RSE) market. The said research study covers in-depth analysis of affected patient population and its segmentation by geography. The report covers the patient population by gender as well as by age along with all the assumptions considered in different geographies.
Patient Segmentation
- Patient Population of Status Epilepticus (SE)
- Patient Population of Status Epilepticus (SE) by Type
- Patient Population of Status Epilepticus (SE) by Age
- Number of Status Epilepticus (SE) Patients on First Line Treatment
- Number of Established Status Epilepticus Patients on Second Line Treatment
Regional Segmentation
- Europe
- Germany
- Italy
- France
- United Kingdom
- Spain
- North America
- United States
- Asia Pacific
- Japan
Table of Contents
1.Table of Contents
2. Preface
3. Executive Summary
4. Key Insights
5. Refractory Status Epilepticus (RSE)
7. Seven Major Markets Epidemiology and Segmentation
8. Epidemiology by Countries
9. What do physicians think?
10. Conclusion
List of Tables
List of Figures
Samples
LOADING...
